(secondQuint)A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne.

 This is a multi-center, evaluator and subject blinded, randomized, vehicle-controlled, parallel group, dose-ranging study to be conducted in approximately 150 subjects with acne vulgaris.

 Subjects who satisfy the entry criteria at the Baseline visit will be randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel in a 1:1:1 ratio.

 Efficacy assessments will include inflammatory and non-inflammatory lesion counts and investigator global assessments (IGA).

 Tolerability and safety assessments include cutaneous tolerability evaluation, adverse event collection, physical exams, and laboratory studies.

 Subjects will return for post-baseline evaluation at Weeks 2, 4, 8, and 12.

.

 A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne@highlight

This is a 12 week clinical trial in subjects with acne vulgaris.

 Subjects will be randomized to NVN1000 1% Gel, NVN1000 4% Gel or Vehicle Gel twice daily.

 Safety, tolerability and efficacy will be assessed over the course of the study.

